美国血液学会COVID-19血栓预防抗凝活指南:2021年5月更新——危重症患者中强度抗凝的使用
美国血液学会(ASH)制定多学科指南小组,应用GRADE方法,系统评价截至2021年3月5日的证据,形成关于COVID-19相关危重症患者血栓预防抗凝的推荐。本次2021年5月更新新增1条推荐:对无确诊或疑似VTE的COVID-19相关危重症患者,条件性推荐预防强度抗凝优于中等强度抗凝。该推荐基于低确定性证据,强调需要更多高质量随机对照试验比较不同抗凝强度。其他研究重点包括危重症患者血栓和出血风险预测因素,以及非抗凝治疗(如抗病毒药物、糖皮质激素)对血栓风险的影响。
要点
- 对无确诊或疑似VTE的COVID-19相关危重症患者,ASH条件性推荐预防强度抗凝优于中等强度抗凝(低确定性证据)。
- 该推荐为条件性推荐,基于低确定性证据,不是强推荐。
- 证据确定性低,强调需要更多高质量随机对照试验比较不同抗凝强度。
- 研究重点还包括危重症COVID-19患者血栓和出血风险的预测因素。
- 研究重点还包括非抗凝治疗(如抗病毒药物、糖皮质激素)对血栓风险的影响。
适用人群与场景
- COVID-19相关危重症且无确诊或疑似VTE的患者。
处置流程与药物剂量
- 对无确诊或疑似VTE的COVID-19相关危重症患者,条件性推荐预防强度抗凝优于中等强度抗凝(低确定性证据)。
研究设计与关键结果
- ASH多学科指南小组应用GRADE方法,系统评价截至2021年3月5日的证据,本次2021年5月更新新增1条推荐:对无确诊或疑似VTE的COVID-19相关危重症患者,条件性推荐预防强度抗凝优于中等强度抗凝。
证据类型、等级与局限
- 证据类型:指南(美国血液学会活指南)。
- 推荐强度:条件性推荐(低确定性证据)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于无确诊或疑似VTE的COVID-19相关危重症患者,ASH条件性推荐预防强度抗凝优于中等强度抗凝(低确定性证据)。
- 该推荐基于低确定性证据,强调需要更多高质量随机对照试验比较不同抗凝强度。
指南或共识出处
- 美国血液学会(ASH)COVID-19患者血栓预防抗凝活指南:2021年5月更新(Blood Adv)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: COVID-19-related critical illness is associated with an increased risk of venous thromboembolism (VTE).
OBJECTIVE: These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in making decisions about the use of anticoagulation for thromboprophylaxis in patients with COVID-19-related critical illness who do not have confirmed or suspected VTE.
METHODS: ASH formed a multidisciplinary guideline panel that included 3 patient representatives and applied strategies to minimize potential bias from conflicts of interest. The McMaster University Grading of Recommendations Assessment, Development and Evaluation (GRADE) Centre supported the guideline development process by performing systematic evidence reviews (up to 5 March 2021). The panel prioritized clinical questions and outcomes according to their importance for clinicians and patients. The panel used the GRADE approach to assess evidence and make recommendations, which were subject to public comment. This is an update on guidelines published in February 2021.
RESULTS: The panel agreed on 1 additional recommendation. The panel issued a conditional recommendation in favor of prophylactic-intensity over intermediate-intensity anticoagulation in patients with COVID-19-related critical illness who do not have confirmed or suspected VTE.
CONCLUSIONS: This recommendation was based on low certainty in the evidence, which underscores the need for additional high-quality, randomized, controlled trials comparing different intensities of anticoagulation in critically ill patients. Other key research priorities include better evidence regarding predictors of thrombosis and bleeding risk in critically ill patients with COVID-19 and the impact of nonanticoagulant therapies (eg, antiviral agents, corticosteroids) on thrombotic risk.
参考来源
- Cuker A, Tseng EK, Nieuwlaat R, et al. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in critically ill patients. Blood Adv. 2021. PMID: 34474482. doi:10.1182/bloodadvances.2021005493
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。